Dry Eye Disease Clinical Trial
— heiQOfficial title:
Assessing a Self-care Management Program for Dry Eye Disease Patients Using the Health Educational Intervention Questionnaire
Verified date | May 2019 |
Source | Lawson Health Research Institute |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Dry Eye Disease (DED)is a chronic disease without a cure. Empowering patients to engage in better self-care requires knowledge of their disease and skills in self-management, which can lead to improved well-being and quality of life. The Investigation team has developed a DED self-management program (video series and educational booklet) that can be easily implemented into clinical use. The Investigators are going to use the Ocular Surface Disease Index (OSDI) to measure the dry eye in the participants. In addition, the research team plans to use the heiQ (validated questionnaire that assesses self-management and health education programs) to evaluate the DED self-management program by comparing results taken at baseline to 2 months after undergoing the self-management program.
Status | Active, not recruiting |
Enrollment | 130 |
Est. completion date | July 30, 2020 |
Est. primary completion date | January 19, 2019 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility |
Inclusion Criteria: - Participants will be considered eligible for inclusion in the study if they are: 1. moderate to severe dry eye disease patients (have a minimum score of 20 on the Ocular Surface Disease Index and minimum score of 5 on the Canadian Dry Eye Assessment) 2. at least 18 years of age 3. capable of communicating in English 4) willing and able to receive the educational intervention 5) willing and able to conduct DED self-care at home as needed Exclusion Criteria: Participants will be considered ineligible for participation in the study if any of the following criteria are met: 1. They are currently participating in other similar studies 2. They are currently undergoing or have undergone any type of self-care management/educational program for dry eye disease 3. unable/unwilling to receive the educational intervention and complete the two administrations of the heiQ 4 ) Unable to communicate fluently in English as the videos and the heiQ survey are both only available in English. |
Country | Name | City | State |
---|---|---|---|
Canada | St. Joseph's Hospital | London | Ontario |
Lead Sponsor | Collaborator |
---|---|
Lawson Health Research Institute |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Mean Change score in heiQ subscales | Mean change in scores of each of the eight heiQ subscales from baseline to 2-months post-intervention for each arm of the study | 2 months | |
Secondary | Mean Change scores in OSDI scores | Mean change in scores of OSDI from baseline to 2 month post-intervention for each arm of the study | 2 Months | |
Secondary | Mean change score in heiQ subscale 1:Health-directed activity | mean change score in the heiQ subscale 1 (Health-directed activity) from baseline to 2-months post intervention for each arm of the study | 2 months | |
Secondary | Mean change score in heiQ subscale 1: Health-Directed activity | Mean change score in the heiQ subscale 1 (Health-directed activity) from baseline to 2- month post intervention for each individual participant | 2 months | |
Secondary | Mean change score in heiQ subscale 2: Positive and active engagement in life | Mean change score in heiQ subscale 2 (Positive and active engagement in life) from baseline to 2-months post-intervention for each arm of the study | 2 months | |
Secondary | Mean change score in heiQ subscale 2: Positive and active engagement in life | Mean change score in the heiQ subscale 2 (Positive and active engagement in life) from baseline to 2-months post-intervention for each individual participant | 2 months | |
Secondary | Mean change score in heiQ subscale 3: Self-monitoring and insight | Mean change score in the heiQ subscale 3 (Self-monitoring and insight) from baseline to 2-months post-intervention for each arm of the study | 2 months | |
Secondary | Mean change score in heiQ subscale 3: Self-monitoring and insight | Mean change score in the heiQ subscale 3 (Self-monitoring and insight) from baseline to 2-months post-intervention for each individual participants | 2 months | |
Secondary | Mean change score in heiQ subscale 4: Constructive attitudes and approaches | Mean change score in the heiQ subscale 4 (Constructive attitudes and approaches) from baseline to 2-months post-intervention for each arm of the study | 2 months | |
Secondary | Mean change score in heiQ subscale 4: Constructive attitudes and approaches | Mean change score in the heiQ subscale 4 (Constructive attitudes and approaches) from baseline to 2-months post-intervention for each individual participant | 2 months | |
Secondary | Mean change score in heiQ subscale 5: Skill and technique acquisition | Mean change score in the heiQ subscale 5 (Skill and technique acquisition) from baseline to 2-months post-intervention for each arm of the study | 2 months | |
Secondary | Mean change score in heiQ subscale 5: Skill and technique acquisition | Mean change score in the heiQ subscale 5 (Skill and technique acquisition) from baseline to 2-months post-intervention for each individual participant | 2 months | |
Secondary | Mean change score in heiQ subscale 6: Social integration and support | Mean change score in the heiQ subscale 6 (Social integration and support) from baseline to 2 months post intervention for each arm of the study | 2 months | |
Secondary | Mean change score in heiQ subscale 6: Social integration and support | Mean change score in heiQ subscale 6 (Social integration and support) from baseline to 2 months post intervention for each individual participant | 2 months | |
Secondary | Mean change score in the heiQ subscale 7: Health service navigation | Mean change score in heiQ subscale 7 ( Health service navigation) from baseline to 2-months post-intervention for each arm of the study | 2 months | |
Secondary | Mean change score in the heiQ subscale 7: Health service navigation | Mean change score in heiQ subscale 7 ( Health service navigation) from baseline to 2-months post-intervention for each individual participant | 2 months | |
Secondary | Mean change score in heiQ subscale 8: Emotional distress | Mean change score in heiQ subscale 8 (Emotional Distress) from baseline to 2-months post intervention for each arm of the study | 2 months | |
Secondary | Mean change score in heiQ subscale 8: Emotional distress | Mean change score in heiQ subscale 8 (Emotional Distress) from baseline to 2-months post intervention for each individual participant | 2 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03216096 -
Assessing Safety and Efficacy of DE-089 Ophthalmic Solution in Patients With Dry Eye Disease
|
Phase 1 | |
Completed |
NCT05825599 -
PMCF Study to Evaluate Performance and Safety of "HPMC-based Eyedrops" Used to Relieve Dry Eye Symptoms
|
N/A | |
Completed |
NCT04656197 -
The Ocular Microbiome in Patients With Dry Eye Disease
|
||
Completed |
NCT05031806 -
Evaluation of the Safety, Tolerability and Efficacy of iNexin™ for the Treatment of the Signs and Symptoms Associated With Dry Eye Disease
|
Phase 1 | |
Completed |
NCT03688802 -
Efficacy of OC-01 Nasal Spray on Goblet Cell and Meibomian Gland Stimulation
|
Phase 2 | |
Completed |
NCT05213156 -
Concentration of Ofloxacin Into the Aqueous Humour of Patients With Dry Eye Disease
|
Phase 4 | |
Completed |
NCT04548427 -
Study to Evaluate the Efficacy and Safety of CKD-352
|
Phase 3 | |
Completed |
NCT06176651 -
Evaluation of Miebo (Perfluorohexyloctane) Eyedrops in Habitual Contact Lens Wearers
|
Phase 4 | |
Completed |
NCT02254265 -
Phase 2/3 Dose-Ranging Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca
|
Phase 2/Phase 3 | |
Completed |
NCT00395759 -
The Visual Effect of an Investigational Artificial Tear in the Tear Layer.
|
N/A | |
Completed |
NCT00680108 -
A Study to Determine the Safety and Tolerability of Escalating Doses of INS365 Ophthalmic Solution
|
Phase 2 | |
Recruiting |
NCT06064071 -
Clinical Study Evaluating Nordlys™ SWT IPL for Dry Eye Disease (DED) Due to MGD
|
N/A | |
Completed |
NCT04139122 -
Safety, PK and Efficacy Study of SJP-0132 in Subjects With Dry Eye Disease
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06375343 -
Study to Evaluating PRO-240 Ophthalmic Solution Compared to Optive®
|
Phase 1 | |
Completed |
NCT01468168 -
A Study Assessing the Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients
|
Phase 2 | |
Completed |
NCT01014078 -
A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Dry Eye Disease
|
Phase 4 | |
Completed |
NCT00799682 -
Exploratory Study Comparing Signs and Symptoms in Patients With Ocular Hypertension or Glaucoma Using Xalatan R® or Travatan Z®
|
Phase 4 | |
Completed |
NCT05082974 -
Investigator Initiated Study to Assess the Efficacy of OC-01 (Varenicline) Nasal Spray on Signs and Symptoms of Dry Eye Disease Following Laser-assisted in Situ Keratomileusis (LASIK)
|
Phase 3 | |
Recruiting |
NCT06146881 -
Effectiveness of Diquafosol Prophylactic Therapy to Prevent Dry Eye Disease for Cataract Surgery Patients in Indonesia
|
Phase 2 | |
Completed |
NCT03292809 -
CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)
|
Phase 2/Phase 3 |